Case reportPublished 26 Jun 2018
Is the Target therapy have a role in the treatment of Metastatic lung cancer in patients who is not fit for chemotherapy? Case Report
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Introduction: Lung cancer is the most common cause of cancer death worldwide, with an estimated 1.6 million deaths each year. Approximately 85% of patients have a group of histological subtypes collectively known as NSCLC, of which lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the most common subtypes. Epidermal growth factor receptor (EGFR) and its mutations are found to have an important role in this cancer. Therefore, EGFR tyrosine kinase inhibitors (TKIs) can work effectively against NSCLC. Gefitinib and Erlotinib, which are a first generation TKI, and Afatinib, which is a second-generation TKI, are effective as a first-line therapy for advanced NSCLC. Case report: We describe here a case of a 52 years old Saudi female nonsmoker who was diagnosed as a case of adenocarcinoma of lung origin with brain and inguinal lymph node metastasis. The patient underwent urgent brain surgery, received palliative radiotherapy and due to his poor general condition, she cannot received chemotherapy and started on Erlotinb before molecular study results and fortunately, the patient get excellent clinical response with good radiological response.
Keywords
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Medical Oncology
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Ayman Rasmy”
- BylineArticles whose byline prints “Mohamed Mashiaki”
- BylineArticles whose byline prints “Amal Ameen”
